Cell News and Research

RSS

Ipilimumab in combination with paclitaxel/carboplatin for stage IIIb/IV NSCLC shows superior results

Ipilimumab used in combination with paclitaxel/carboplatin for stage IIIb/IV non-small cell lung cancer showed superior results in progression free survival when compared to paclitaxel/carboplatin alone, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and the University of Chicago.

10 Dec 2010

Epigenetic-molecular targeted therapy combination holds promise against advanced lung cancer

A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and The University of Chicago.

10 Dec 2010

PLD/carboplatin to replace paclitaxel/carboplatin as gold-standard treatment for platinum-sensitive ovarian cancer

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although platinum-based treatment will continue to be the standard of care for first- and second-line treatment of platinum-sensitive ovarian cancer, pegylated liposomal doxorubicin (PLD)/carboplatin will replace paclitaxel/carboplatin as the standard second-line treatment for patients who remain platinum sensitive.

10 Dec 2010

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone. These results were presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.

10 Dec 2010

Harvard Bioscience files two major patents in regenerative medicine

Harvard Bioscience, Inc., a global developer, manufacturer and marketer of a broad range of specialized products used to advance life science research and regenerative medicine, has filed two major patents in the field of regenerative medicine, the first covering 61 claims for its stem cell therapy injectors and the second for 338 claims for bioreactors for organ growth.

From Harvard Bioscience 10 Dec 2010

Entinostat plus erlotinib improves survival in NSCLC patients with elevated E-cadherin

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces clinical results from ENCORE 401, a double-blind, placebo-controlled phase 2 trial, in patients with advanced non-small cell lung cancer (NSCLC). The results show that there was a survival advantage in the subset of patients with elevated E-cadherin (a molecular marker of epithelial tumors) receiving entinostat in combination with erlotinib (Tarceva®).

10 Dec 2010

GeoVax's phase 2a trial results indicate excellent safety profile for HIV vaccine

GeoVax Labs, Inc., announced today that early results from part A of an ongoing phase 2a clinical trial indicate an excellent safety profile and highly reproducible immunogenicity.

10 Dec 2010

Fibrin microthreads support mesenchymal stem cell growth

A research team at Worcester Polytechnic Institute has demonstrated the feasibility of a novel technology that a surgeon could use to deliver stem cells to targeted areas of the body to repair diseased or damaged tissue, including cardiac muscle damaged by a heart attack. The technique involves bundling biopolymer microthreads into biological sutures and seeding the sutures with stem cells. The team has shown that the adult bone-marrow-derived stem cells will multiply while attached to the threads and retain their ability to differentiate and grow into other cell types.

10 Dec 2010

Horizon Discovery licenses new human isogenic cell models from Case Western Reserve

With the goal of developing new, more effective and personalized cancer treatments, Horizon Discovery, based in Cambridge, England, has secured from Case Western Reserve University exclusive rights to a panel of new human isogenic cell models developed by the laboratory of Zhenghe Wang, assistant professor of genetics at the university's School of Medicine.

10 Dec 2010

Celulas Genetica to submit international patent application for Rutherford Procedure

Emerging Healthcare Solutions, Inc. announced today that its newly acquired biotechnology division Celulas Genetica will submit an international patent application for the Rutherford Procedure, a revolutionary new stem-cell treatment for liver disease.

10 Dec 2010

Horizon Discovery secures exclusive rights to human isogenic cell models

With the goal of developing new, more effective and personalized cancer treatments, Horizon Discovery, based in Cambridge, England, has secured from Case Western Reserve University exclusive rights to a panel of new human isogenic cell models developed by the laboratory of Zhenghe John Wang, assistant professor of genetics at the university's School of Medicine.

10 Dec 2010

New molecular tools show promise for cleansing brain of amyloid plaques

New molecular tools developed at the University of Michigan show promise for "cleansing" the brain of amyloid plaques, implicated in Alzheimer's disease.

10 Dec 2010

Researchers target MIC-1 protein to halt growth of melanoma tumors

Halting the growth of melanoma tumors by targeting the MIC-1 protein that promotes blood vessel development in tumors may lead to better treatment of this invasive and deadly cancer, according to Penn State College of Medicine researchers in The Foreman Foundation Research Laboratory.

10 Dec 2010

Biovex announces OncoVEXGM-CSF Phase 3 study for head and neck cancer

BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer and infectious disease, announced today that a Phase 3 pivotal study with OncoVEXGM-CSF for the first line treatment of patients with locally advanced squamous cell carcinoma of the head & neck has commenced.

10 Dec 2010

NCCN announces new guidelines for patients with multiple myeloma

The National Comprehensive Cancer Network recently announced the latest addition to the library of NCCN Guidelines for Patients, the NCCN Guidelines for Patients: Multiple Myeloma. This new resource is a patient-friendly translation of the NCCN Clinical Practice Guidelines in Oncology for Multiple Myeloma, which physicians use when determining appropriate cancer treatment.

10 Dec 2010

Clinical, preclinical results of ISF35 in CLL patients presented at ASH 2010

Memgen, LLC announced the presentation of clinical and preclinical results for its lead product, ISF35, during the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida. The research and clinical development of ISF35 announced today was led by Januario Castro, MD, and Thomas Kipps, MD, PhD, both at the University of California, San Diego.

10 Dec 2010

Clearance of plaque-forming substance is impaired in Alzheimer's disease

"Clearance is impaired in Alzheimer's disease," says Randall Bateman, MD, assistant professor of neurology at Washington University School of Medicine in St. Louis.

10 Dec 2010

Some key molecular events in immune system contribute to inflammatory bowel disease: Scientists

Scientists at the Virginia Bioinformatics Institute at Virginia Tech have discovered some of the key molecular events in the immune system that contribute to inflammatory bowel disease. The results, which help researchers move one step further in their efforts to develop new drugs to treat inflammatory and immune-mediated diseases, are reported in the November 2010 edition of the journal Mucosal Immunology from the Nature Publishing Group.

10 Dec 2010

Researchers verify several factors associated with increased risk of brain metastases in breast cancer patients

Nearly one-fifth of all metastatic breast cancer patients develop brain metastases and have significantly shorter overall survival than patients who do not have brain involvement. One way to improve the affected patients' survival might be to prevent the brain metastases from arising in the first place. With that in mind, researchers have been working on a predictive model that accurately identifies these high risk patients.

10 Dec 2010

New three-drug combination may be effective for newly diagnosed blood cancer patients: Study

A new three-drug combination used to treat the blood cancer multiple myeloma may be effective as a front-line therapy for newly diagnosed patients, according to a study led by the University of Michigan Comprehensive Cancer Center.

9 Dec 2010

Cell News and Research

Ipilimumab in combination with paclitaxel/carboplatin for stage IIIb/IV NSCLC shows superior results

Epigenetic-molecular targeted therapy combination holds promise against advanced lung cancer

PLD/carboplatin to replace paclitaxel/carboplatin as gold-standard treatment for platinum-sensitive ovarian cancer

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

Harvard Bioscience files two major patents in regenerative medicine

Entinostat plus erlotinib improves survival in NSCLC patients with elevated E-cadherin

GeoVax's phase 2a trial results indicate excellent safety profile for HIV vaccine

Fibrin microthreads support mesenchymal stem cell growth

Horizon Discovery licenses new human isogenic cell models from Case Western Reserve

Celulas Genetica to submit international patent application for Rutherford Procedure

Horizon Discovery secures exclusive rights to human isogenic cell models

New molecular tools show promise for cleansing brain of amyloid plaques

Researchers target MIC-1 protein to halt growth of melanoma tumors

Biovex announces OncoVEXGM-CSF Phase 3 study for head and neck cancer

NCCN announces new guidelines for patients with multiple myeloma

Clinical, preclinical results of ISF35 in CLL patients presented at ASH 2010

Clearance of plaque-forming substance is impaired in Alzheimer's disease

Some key molecular events in immune system contribute to inflammatory bowel disease: Scientists

Researchers verify several factors associated with increased risk of brain metastases in breast cancer patients

New three-drug combination may be effective for newly diagnosed blood cancer patients: Study

Industry focus eBook - Cell and gene therapy (2nd edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics